Raloxifeno [Spanish]
Categoria
Raloxifeno [Spanish] Nombres de marca, Raloxifeno [Spanish] Analogos
Raloxifeno [Spanish] Marca los nombres de mezcla
Raloxifeno [Spanish] Formula quimica
C28H27NO4S
Raloxifeno [Spanish] RX enlace
http://www.rxlist.com/cgi/generic/raloxif.htm
Raloxifeno [Spanish] FDA hoja
Raloxifeno [Spanish] MSDS (hoja de seguridad de materiales)
Raloxifeno [Spanish] Sintesis de referencia
CD Jones et al., J. Med. Cem. 27, 1057 (1984)
Raloxifeno [Spanish] Peso molecular
473.584 g/mol
Raloxifeno [Spanish] Punto de fusion
143-147oC
Raloxifeno [Spanish] H2O Solubilidad
0.25 mg / L
Raloxifeno [Spanish] Estado
Solid
Raloxifeno [Spanish] LogP
5.749
Raloxifeno [Spanish] Formas de dosificacion
Tableta
Raloxifeno [Spanish] Indicacion
Para la prevención de la osteoporosis en mujeres post-menopáusicas
Raloxifeno [Spanish] Farmacologia
El raloxifeno, un modulador selectivo del receptor de estrógeno (SERM) de la clase benzotiofeno, es similar al tamoxifeno, ya que produce efectos similares al estrógeno en el hueso y el metabolismo lipídico, mientras que antagonizar los efectos del estrógeno sobre el tejido mamario. El raloxifeno disminuye la resorción ósea, aumenta la densidad mineral ósea (DMO) y disminuye la incidencia de fracturas. El raloxifeno se utiliza en la prevención de la menopausia la osteoporosis y el cáncer de mama.
Raloxifeno [Spanish] Absorcion
Aproximadamente el 60% de una dosis oral se absorbe, pero glucuronoconjugación presistémico es muy amplia. La biodisponibilidad absoluta de raloxifeno es del 2,0%
Raloxifeno [Spanish] Toxicidad
No hay información disponible
Raloxifeno [Spanish] Informacion de Pacientes
PATIENT INFORMATION
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
Raloxifeno [Spanish] Organismos afectados
Humanos y otros mamíferos
![Raloxifeno_[Spanish]](/images/rx/APRD00400.gif)
